TITLE

Cancer treatment more targeted, deaths decline

AUTHOR(S)
Pfeiffer, Naomi
PUB. DATE
July 2007
SOURCE
Drug Topics;7/23/2007, Vol. 151 Issue 14, p19
SOURCE TYPE
Trade Publication
DOC. TYPE
Proceeding
ABSTRACT
The article highlights the American Society of Clinical Oncology's annual meeting in Chicago, Illinois. It focuses on the phase III trial of sorafenib revealing that advanced liver cancer patients receiving the targeted drug live much longer than other patients with the lethal disease. It discusses the first phase II trial of aflibercept's effectiveness against epithelial ovarian cancer. Amgen also presents the results of a phase II trial of motesanib diphosphate in patients with thyroid cancer.
ACCESSION #
26131618

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics